article thumbnail

Report: Percentage of Workers Eligible for Employment-Based Coverage Increased 5% Since 2014

MedCity News

It was expected that the Affordable Care Act would lead to many employers dropping health benefits, but that did not happen, a new report from the Employee Benefit Research Institute found.

Leads 298
article thumbnail

What the 2014 Ebola outbreak taught this biotech CEO about persuasion

PharmaVoice

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

Leads 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Preparing for a new era in the rare disease sector

European Pharmaceutical Review

For documents published in 2014 this number was just six; in 2024 it was 157 ( Figure 2 ). 2014-2024 (Credit: Elsevier BV – Scopus) Figure 2 : Documents by year. 2014-2024 (Credit: Elsevier BV – Scopus) Regionally, the US is dominating rare disease research. 1 Figure 1 : Documents by year.

article thumbnail

Takeda plans 2026 CEO succession

European Pharmaceutical Review

He joined Takeda as CEO in April 2014. Christophe Weber is set to retire as Chief Executive Officer (CEO) of Takeda in June 2026 after 12 years.Julie Kim, president of Takedas US Business Unit has been appointed as Webers successor. Weber is the companys current President, CEO and representative director.

article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.

Pharma 255
article thumbnail

Developing an effective contamination control strategy

European Pharmaceutical Review

The panelists referred to other documents that are useful for CCS development: the 2014 Pharmaceutical Healthcare Sciences Society (PHSS) Technical Monograph No 20 Bio-Contamination 2 as well as the Parenteral Drug Association (PDA) Technical Report 90: Contamination Control Strategy Development, 3 published in February 2023.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. This leads to a question; “where does it end?” COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.

Pharma 210